2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…
We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…
We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…
FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…
Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…
Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…